2月20日 - ** 制药公司BioMarin Pharmaceutical BMRN.O股价盘前上涨10.5%至72.51美元。
** 周三收盘后，该公司公布第四季度营收为7.47亿美元，高于预期的7.134亿美元。
** 第四季度每股收益 92 美分，高于预期的 53 美分。
** 预测 2025 年每股副利润介于 4.20 美元至 4.40 美元之间，高于预期的每股 3.26 美元
** 券商 Evercore ISI 认为 BMRN 的第四季度业绩 "稳健"；并补充说："看来投资者还是愿意奖励公司稳健的执行力。这确实是一次令人鼓舞的多方面更新"。
** 2024 年股价下跌了 31.8
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.